Spontaneous intracerebral haemorrhage (ICH) is a life-threatening condition, still devoided of specific treatment. Peri-haematomal oedema (PHO) develops in the ensuing days after ICH onset and worsens functional outcome. Hence, PHO is a promising therapeutic target but until now there is no specific treatment for PHO. The occurrence and growth of PHO is mainly mediated by inflammation. We hypothesize that a modulation of inflammation is effective in reducing PHO growth, therefore improving the functional outcome of ICH patients. From animal studies to human post-mortem studies, our team has demonstrated a key role for erythroid-related nuclear factor 2 (Nrf2) in PHO. Indeed, this transcription factor promotes the protective effect of inflammation: Nrf2 activation enhances antioxidant defenses and increases rates of blood resorption. Therefore, Nrf2 emerges as a promising and innovative therapeutic target. Taking into account the prolonged time interval between de novo drug discovery and use in clinical practice, drug repurposing is an interesting option for the unmet clinical need of reducing PHO. We chose Diroximel Fumarate (DRF) which is a safe and effective Nrf2 activator widely used in multiple sclerosis (dimethyl fumarate is on the market since 2013, and DRF since 2019) to modulate inflammation and to establish the efficacy of Nrf2 activation in reducing PHO growth and, ultimately, in improving the functional prognosis after ICH.

Start Date01 Feb 2026

Sponsor / Collaborator

La Santé

IRCT20200105046010N142

/ SuspendedNot Applicable

In vivo bioequivalence study of Diroximel fumarate 231 mg EC .Capsules of zist daru danesh as Test Drug in compared with the reference Drug in Iranian Healthy Volunteers

Start Date23 Jul 2025

Sponsor / Collaborator-

NCT06957808

/ RecruitingNot Applicable

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in 6-12 months and continue to experience psychotic symptoms. Therefore, there is a strong unmet need for new evidence-based treatments to target the neurobiology underlying schizophrenia. There is increasing evidence to indicate that glutathione (GSH), the main brain antioxidant, is abnormal in schizophrenia and may provide a new treatment target. In this study, the investigators plan to determine whether Diroximel Fumarate (DRF) (currently a treatment for a brain disorder called multiple sclerosis) can increase GSH in the brain of patients with schizophrenia using a brain scan (MRI) and explore whether changes in GSH are related to other brain measures (measured with MRI and EEG- which measures electrical activity in the brain), blood markers of GSH, and symptoms. During this study 30 people with schizophrenia will be recruited. Participants will take the drug DRF for two weeks, a computer will then decide randomly whether each person will continue to take DRF or a placebo/dummy pill for another two weeks. During this part of the study neither the patients nor the researchers will know which type of drug the patient is taking. Brain GSH and the other measures described will be assessed before and after taking the DRF and placebo/dummy pill. At the end of the study (2027), the investigators will see if taking DRF alters the brain chemical (GSH) in people with schizophrenia and whether this is linked to other measures and symptoms. It will also give researchers information about the best way to design future studies for patients with schizophrenia using this drug.

Start Date10 Jan 2025

Sponsor / Collaborator

King's College London

[+1]

100 Clinical Results associated with Diroximel fumarate

100 Translational Medicine associated with Diroximel fumarate

100 Patents (Medical) associated with Diroximel fumarate

107

Literatures (Medical) associated with Diroximel fumarate

01 Mar 2026·Multiple Sclerosis and Related Disorders

Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis

Article

Author: Schneider, Megan ; Choi, Leena ; Zuckerman, Autumn ; Banks, Aimee ; DeClercq, Josh ; Cruchelow, Katie R

BACKGROUND:

When treating multiple sclerosis, lymphopenia is an established side effect of fumaric acids. Research demonstrating the impact of switching fumarates on lymphocyte counts is scarce. The objective of this study is to characterize the incidence and severity of lymphopenia in patients transitioning from dimethyl fumarate (DMF) to monomethyl fumarate (MMF) or diroximel fumarate (DRF).

METHODS:

A single center, retrospective review of adult medical records at the Vanderbilt Multiple Sclerosis Clinic who filled prescriptions for DMF then either DRF or MMF between January 1st, 2019 and February 28th, 2023.

RESULTS:

Patients who switched to DRF experienced a greater median percent change in absolute lymphocyte count (ALC) [45% decrease (IQR -95 to -14)] compared to those who switched to MMF [6% increase (IQR -4 to 17)]. Patients who switched to MMF, on average, had an ALC at follow-up 1.8 times higher than those switched to DRF (95% CI 1.4 to 2.3; p < 0.001). Additionally, patients switched to DRF were more likely to experience grade 2 or 3 lymphopenia compared to patients switched to MMF.

CONCLUSION:

Our study demonstrated that patients switched to DRF had a significantly lower ALC at follow-up and were more likely to have lymphopenia compared to patients switched to MMF.

01 Jan 2026·INTERNATIONAL IMMUNOPHARMACOLOGY

Effect of diroximel fumarate on gut dysbiosis and autoimmunity in the central nervous system

Article

Author: Ito, Naoko ; Kalina, J Tamar ; Rosario, Yaritza ; Yadav, Sudhir Kumar ; Dhib-Jalbut, Suhayl ; Ito, Kouichi ; Suresh, Shradha ; Shankar, Sai L

Diroximel fumarate (DRF) is an approved treatment for relapsing-remitting multiple sclerosis (RRMS). It has demonstrated better gastrointestinal tolerability compared to dimethyl fumarate (DMF). Recent studies indicate that gut dysbiosis may contribute to the development of multiple sclerosis (MS) and that reducing gut dysbiosis may be beneficial for disease progression. This study investigated the effects of DRF on gut dysbiosis and neuroinflammation in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We examined the effect of DRF on the expression of α4β1 and α4β7 integrins on CD4 + T cells, which are essential for guiding their migration into the central nervous system (CNS) and the gut, respectively. The expression of α4β1 increased in lymph nodes when EAE was induced, but DRF treatment reduced its expression and the production of IL-17. The expression of α4β7 on T cells was also upregulated in the lymph nodes, and the infiltration of α4β7 + CD4+ T cells into the gut increased following EAE induction. DRF treatment reduced the development of α4β7 + CD4+ T cells in the lymph nodes and their infiltration into the small intestine. This led to a decrease in the gut dysbiosis biomarker, lipocalin 2 (Lcn2), and a reduction in pathogenic bacteria from the Desulfovibrionaceae family in EAE mice. In patients with relapsing-remitting multiple sclerosis (RRMS), treatment with DRF showed a trend toward decreased levels of α4β1 + CD4+ T cells and endotoxin, which is a blood marker of intestinal permeability. Furthermore, DRF reduced the production of CCL22, a chemokine derived from macrophages. Overall, our findings suggest that DRF can reduce neuroinflammation by lowering the production of IL-17, inhibiting the development of α4β1 + CD4+ T cells and α4β7 + CD4+ T cells in the lymph nodes, and alleviating dysfunction associated with gut dysbiosis and intestinal permeability.

15 Nov 2025·Gut and Liver

Early Oral Refeeding in Patients with Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Randomized Controlled Trial

Article

Author: Jang, Dong Kee ; Choi, Young Hoon ; Jung, Min Kyu ; Lee, Sang Hyub ; Han, Sung Yong ; Lee, Jae Min ; Choe, Jung Wan ; Kim, Ha Yan ; Kim, Eui Joo ; Jo, Jung Hyun

Background/Aims:

To assess the safety and efficacy of early oral refeeding (ERF) versus delayed refeeding (DRF) in patients with mild post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).

Methods:

Eligible patients were randomly assigned in a 1:1 ratio to the ERF or DRF group. Eligible patients were randomly assigned in a 1:1 ratio to the ERF or DRF group. In the ERF group, feeding began 24 hours after the diagnosis of PEP; in the DRF group, feeding commenced once normal bowel sounds returned and pain had decreased to a visual analog scale score of <2. The diet was advanced from clear fluids to soft foods according to patient tolerance. Refeeding was temporarily halted if the visual analog scale score reached ≥5 points or if intake was refused due to pain. Resumption required normal amylase/lipase levels, pain relief, and bowel movement restoration. Discharge criteria included patient well-being >24 hours post-diet. The primary outcome was PEP hospitalization duration, and secondary outcomes were the incidence of severe acute pancreatitis, readmission rate (<30 days), and PEP-related mortality rate.

Results:

A total of 80 patients (40 in each ERF and DRF group) were enrolled across nine referral centers. Baseline characteristics, procedural parameters and initial PEP severity were not significantly different between the two groups. Four ERF and three DRF patients had refeeding interruptions. ERF significantly reduced PEP hospitalization duration compared to DRF (2.93±1.59 days vs 3.78±1.97 days: relative risk, 0.75; 95% confidence interval, 0.59 to 0.97; p=0.026). Rates of severe acute pancreatitis, readmission, and mortality/morbidity related to PEP were similar between the two groups.

Conclusions:

ERF effectively shortens hospitalization in mild PEP patients without increasing safety risks (ClinicalTrials.gov identifier NCT04750044).

News (Medical) associated with Diroximel fumarate

23 Feb 2026

·www.biospace.com

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a neurofilament biomarker, and an overall trend of slowing disease progression as measured by the ALSFRS-R Subgroup analysis showed statistically significant effect on ALSFRS-R Interim data support including an open-label extended dosing period to ANQUR protocol; approval received in Canada and under regulatory review in other regions; preparations underway to advance QRL-201 into pivotal Phase 3 clinical trial in 2027 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrated QRL-201 had an effect on disease progression in ALS patients; this effect was confirmed by markers of clinical efficacy and changes in a clinically relevant biomarker, along with target engagement. QRL-201 is a first-in-class, potent antisense oligonucleotide (ASO) precision therapeutic in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. STMN2 is a protein important for muscle innervation that is regulated by TDP-43 and downregulated in the majority of ALS patients. ANQUR (QRL-201-01; NCT05633459) is the first-ever clinical trial to evaluate a potential therapy to rescue STMN2 expression in people with ALS. The ANQUR study is a double-blind, placebo-controlled study which dosed a total of 69 patients across the dose escalation (n=17) and dose-range finding (DRF) (n=52) phases of the study. “I am encouraged by these data from the ANQUR clinical trial of QRL-201. The combination of effects on target engagement biomarkers, disease biomarkers such as neurofilament, and clinical measures is very promising and remarkable to see from an early stage clinical trial,” said Merit E. Cudkowicz, M.D., M.Sc., director, Sean M. Healey & AMG Center for ALS and executive director of the Mass General Brigham Neuroscience Institute, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. “ALS is a devastating, fatal neurodegenerative disease with a significant unmet medical need. Our mission is to make a meaningful difference for people living with ALS. We believe QRL-201 has the potential to modify disease progression and improve outcomes for sporadic ALS patients,” said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. “These results from the ANQUR clinical trial are well aligned with our understanding of STMN2 biology and the potential of STMN2 restoration to have a positive impact on ALS disease progression. We are grateful to the ANQUR clinical trial team, participants and their families, and look forward to advancing the QRL-201 clinical program to deliver a much-needed precision medicine option for people living with ALS.” Results from the interim analysis of the ANQUR clinical trial show: Target engagement, confirmed through tissue analysis, with broad distribution across the spinal cord and motor cortex, statistically significant increased levels of STMN2, above the estimated therapeutic target, and correction of STMN2 mis-splicing, as compared to a cohort of natural history samples. A statistically significant and clinically meaningful reduction in phosphorylated neurofilament heavy (pNfH) in the low dose group. An encouraging trend of slowing decline in ALSFRS-R in sporadic patients, including a strong trend on the gross motor sub-score, which is critical for patient independence. In a post-hoc analysis excluding patients with the highest levels of baseline neurofilament light, which is associated with faster disease progression, there was a statistically significant and clinically meaningful slowing of decline in ALSFRS-R at the six-month (24 week) timepoint in treated sporadic ALS patients compared to placebo. QRL-201 was generally safe and well tolerated with most adverse events (AEs) reported as mild or moderate. During all phases of the study, and most recently in December 2025, the unblinded Data Safety Monitoring Board has recommended the study continue without modification. These data support an open-label extended dosing period to the ANQUR clinical trial protocol under which all eligible trial participants will be given the opportunity to receive QRL-201 at the low dose of the DRF portion of the study. The open-label extended dosing period to the ANQUR clinical trial has been approved in Canada and is currently under regulatory review in the European Union and the United Kingdom. In parallel, QurAlis is preparing to advance QRL-201 into a pivotal Phase 3 clinical trial in 2027. About STATHMIN-2 STATHMIN-2 (STMN2) is a well-validated protein important for neural repair, axonal stability, and muscle innervation and is the most significantly regulated gene by TDP-43 exclusively in humans. STMN2 has the most consistently decreased expression across multiple ALS RNA expression studies. Loss of nuclear TDP-43 leads to mis-splicing of the pre-mRNA of STMN2, resulting in loss of full-length transcript and protein. QRL-201 rescues STMN2 loss of function and neurodegenerative phenotypes in QurAlis’ ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. TDP-43 pathology is associated with nearly all ALS patients, approximately 50 percent of patients with frontotemporal dementia (FTD), the second most common form of dementia, and with about a third of Alzheimer’s Disease (AD) patients. There are currently no cures for ALS or FTD, and there are limited therapeutic options available for ALS and FTD patients who are in desperate need of effective therapies. About ANQUR Clinical Trial QRL-201 is being evaluated in the Phase 1/2 ANQUR clinical trial (QRL-201-01; NCT05633459), the first-ever clinical study designed to assess a potential therapy aimed at rescuing STATHMIN-2 (STMN2) expression in people with amyotrophic lateral sclerosis (ALS). The ANQUR trial completed the dose-escalation phase, based on pharmacokinetic analyses from Cohorts 1 and 2 that demonstrated cerebrospinal fluid exposure levels of QRL-201 met or exceeded the targeted therapeutic range. The study then advanced to the dose range-finding phase, which is evaluating two dose levels of QRL-201 and incorporates additional biomarker assessments. The study is currently active in Canada, the United Kingdom, and the European Union, and includes participants with both sporadic ALS and C9orf72-related ALS. More information about the ANQUR clinical trial can be found at . About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn . Contacts Kathy Vincent kathy.vincent@quralis.com

Clinical ResultPhase 3

20 Feb 2026

·firstwordpharma.com

Biopharma bites: Blockbuster hopes for Brinsupri, Biogen stops MS study, plus mRNA patent fight heats up

Insmed guides for $1B in Brinsupri salesBiogen bins mid-stage MS studyModerna's mNEXSPIKE faces patent suitInsmed guides for $1B in Brinsupri salesHaving been approved in the US last August, and subsequently authorised in the EU, as the first treatment for non-cystic fibrosis bronchiectasis (NCFB), Insmed now expects Brinsupri (brensocatib) to generate revenue of at least $1 billion in 2026. "Our US commercial launch…continues to exceed our expectations," said CEO Will Lewis.The oral, once-daily DPP1 inhibitor — designed to block the activation of neutrophil serine proteases in neutrophils that are responsible for the underlying inflammation in NCFB — generated sales of $144.6 million in the fourth quarter of 2025 and $172.7 million for the full year.Insmed expects regulatory decisions for Brinsupri for the treatment of NCFB in the UK and Japan in 2026. However, the company cautioned that it "continues to evaluate the potential effect of evolving US policies," which could impact the timing of potential international commercial launches.-Matthew DennisBiogen bins mid-stage MS study Biogen this week terminated the Phase II FUSION study evaluating BIIB091 in patients with relapsing multiple sclerosis (MS), according to an update on ClinicalTrials.gov. The candidate, a reversible, non-covalent BTK inhibitor, was being studied alone or in combination with diroximel fumarate; the trial had enrolled 127 patients. The study discontinuation comes as at least one BTK inhibitor seems to have found its footing in MS. While the drug class has shown tantalising promise in treating the disease, none have yet reached the finish line — though Roche's fenebrutinib may be nearing approval (see – Physician Views Results: Neurologists share cautious optimism for Roche's fenebrutinib in PPMS).However, Sanofi was recently hit with a controversial FDA rejection for its BTK inhibitor, tolebrutinib, to treat non-relapsing secondary progressive MS. For more on how BTK inhibitors may shake up the MS treatment landscape, see KOL Views Q&A: What Sanofi’s PERSEUS, Roche’s FENtrepid divergence says about BTK inhibitors in MS.-Elizabeth EatonModerna's mNEXSPIKE faces patent suit BioNTech has filed a patent infringement lawsuit alleging that Moderna's next-generation COVID-19 vaccine unlawfully infringes on a patent related to the German company's own mRNA shot, Comirnaty. The complaint, filed Thursday in US District Court for the District of Delaware, claims Moderna's mNEXSPIKE infringes US Patent No. 12,133,899, which covers a streamlined mRNA vaccine design that allows for lower dosing. The case intensifies a long-running legal battle between the companies behind two of the world's most successful COVID-19 vaccines. BioNTech developed Comirnaty with Pfizer, while Moderna brought its own shot, Spikevax, to market in late 2020. In 2022, Moderna sued BioNTech and Pfizer, claiming they "unlawfully copied" its mRNA inventions to make Comirnaty; that case remains ongoing. Moderna recently highlighted mNEXSPIKE, which was approved by the FDA in 2025, as a significant growth driver with expected approvals this year in Europe and Japan. According to BioNTech's complaint, mNEXSPIKE accounted for 55% of COVID-19 vaccines sold by Moderna in the 2025-2026 respiratory virus season. A spokesperson for Moderna said Thursday it would defend itself against the new allegations.-Anna Bratulic

Drug ApprovalPhase 2VaccinemRNAPatent Infringement

19 Feb 2026

·www.fiercebiotech.com

Novartis winds down ph. 1 solid tumor program after lacking efficacy

Novartis had previously shared data from the phase 1 study of QEQ278 showing that none of the patients achieved an objective response.\n Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease.The pharma giant halted the phase 1 trial of QEQ278 and has dropped the candidate entirely, a spokesperson confirmed with Fierce Biotech. Novartis had previously shared early data from the trial showing that none of the patients treated with the protein achieved an objective response, with 26 of them halting treatment partway through the trial because their cancer got worse. Patients included in the trial had advanced malignancies and exhausted standard of care treatments.“Following review in 2024, Novartis made the decision to discontinue development of QEQ278 in the phase 1 study,” the spokesperson told Fierce. “This decision was not based on any safety concern and the asset was removed from the Novartis pipeline.”Despite the discontinuation occurring years ago, the trial’s status was only just updated “per protocol” after “the remaining participant recently discontinued study treatment,” the spokesperson added.News of the terminated trial was first reported by ApexOnco. QEQ278 was designed to target a group of proteins that bind to the natural killer group 2D receptor (NKG2D) on the surface of natural killer (NK) cells. Many tumor cells are littered with ligands that bind to NKG2D, which normally, the natural killer cells, could use to identify the cancer and destroy it. As a decoy, these cancers tend to shed some of the ligands into the bloodstream, which distracts the immune cells and allows the tumor to evade detection.With QEQ278, Novartis hoped to both nullify the decoy ligands floating in the body and also attach to the surface of tumor cells and flag them for destruction.Other companies have also tried to target NKG2D ligands, with limited success. For example, Nkarta engineered NK cells to express a boosted NKG2D receptor and saw some early wins in blood cancer, but ultimately dropped the candidate in March 2024 after the response rate plummeted when more patients were treated.Astellas similarly canned an early CAR-T lymphoma candidate using NKG2D in January 2025, which a company spokesperson told Fierce at the time was a “difficult decision” driven by “prioritization efforts.”Novartis’ decision coincides with Biogen discontinuing a combination arm of a phase 2 trial for multiple sclerosis candidate BIIB091. While Biogen is no longer testing the asset in combination with Vumerity (diroximel fumarate) as a “strategic decision,” monotherapy data for BIIB091 is still expected in the second quarter of 2026, a spokesperson told Fierce.

Phase 1PROTACsPhase 2Clinical Trial Termination

100 Deals associated with Diroximel fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D11154	Diroximel fumarate	L03	DB14783

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	European Union	BIOGEN NETHERLANDS BV	15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting	Iceland	BIOGEN NETHERLANDS BV	15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting	Liechtenstein	BIOGEN NETHERLANDS BV	15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting	Norway	BIOGEN NETHERLANDS BV	15 Nov 2021
Multiple Sclerosis	Switzerland	Biogen, Inc.	20 Sep 2021
Multiple sclerosis relapse	United States	Biogen, Inc.	29 Oct 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gangliosidosis, GM1	Phase 3	United States	Alkermes, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	United States	Biogen, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Belgium	Alkermes, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Belgium	Biogen, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Bulgaria	Alkermes, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Bulgaria	Biogen, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Canada	Biogen, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Canada	Alkermes, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Germany	Alkermes, Inc.	10 Dec 2015
Gangliosidosis, GM1	Phase 3	Germany	Biogen, Inc.	10 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05083923 (CTgov)	Phase 3	Multiple sclerosis relapse	136	DRF 462+DRF (Cohort 1: Japanese Participants)	qmcifbgcwq = vdnqwfrcfk twufacgbjf (cncmgazhew, vyezfhzapt - iesncfkpve) View more	-	24 Oct 2025
				DRF 462+DRF (Cohort 2: Chinese Participants)	qmcifbgcwq = oqrgxpkjxx twufacgbjf (cncmgazhew, wsjiihmkpz - qhlmmksxsu) View more
NCT02634307 (EVOLVE-MS-1, AAN2025)	Phase 3	Gangliosidosis, GM1 \| Multiple Sclerosis, Relapsing-Remitting	1,057	Diroximel Fumarate (DRF)	gnfmxskrzs(tfznqbrpvr) = tvtlzilest bqclxnvjat (ygaokwdpxb, 3.8 - 8.7) View more	Positive	07 Apr 2025
				Ocrelizumab (OCR)	gnfmxskrzs(tfznqbrpvr) = lkjnqtoxpc bqclxnvjat (ygaokwdpxb, 7.1 - 11.1) View more
NCT02634307 (EVOLVE-MS-1, Pubmed)	Phase 3	Multiple Sclerosis, Relapsing-Remitting lymphopenia \| ALC decline	-	Diroximel Fumarate	cotxdlocux(qoikkdlgfl) = fqjrcrjsuw zctksymnov (altwjkhfxt )	Positive	27 Jun 2024
NCT02634307 (EVOLVE-MS-1, Pubmed)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	1,057	Diroximel fumarate	nxklgfsauf(qhqozqqwmt) = cgswvoyzbs wcedodwodc (tksaksbwyh )	Positive	15 Jun 2024
				Dimethyl fumarate	nxklgfsauf(qhqozqqwmt) = pitkcteoyb wcedodwodc (tksaksbwyh )
AAN2024	Not Applicable	Multiple Sclerosis	-	Fumarates (Black)	xxedrsglny(swvaalpmxo) = xnchjmtphr poroydrtvd (sxgsjhppoy, 73.7–80.3)	-	09 Apr 2024
				Fumarates (Hispanic)	xxedrsglny(swvaalpmxo) = ifjdemqbqm poroydrtvd (sxgsjhppoy, 71.0–80.0)
ACTRIMS2024	Not Applicable	Multiple Sclerosis	-	Fumarates (Black)	vkblpwtchg(mvgnuokedc) = drwvrohjap tgiteetevn (wxbtkmlsxx ) View more	-	01 Mar 2024
				Fumarates (Hispanic)	vkblpwtchg(mvgnuokedc) = ubsqxeghde tgiteetevn (wxbtkmlsxx ) View more
SUNBEAM (RPC01-301), RADIANCE phase 3 (RPC01-201B), EVOLVE-MS-1 (ACTRIMS2023)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	-	Ozanimod 1.0 mg	gvfexdozix(hrltgjvflo): risk ratio = 0.924 (95% CI, 0.646 - 1.324) View more	Positive	30 May 2023
				Diroximel fumarate 462 mg
NCT02425644 \| NCT02634307 (EVOLVE-MS-1 \| OPTIMUM, Pubmed)	Phase 3	Multiple sclerosis relapse	-	Diroximel fumarate	zieybtyebe(uvcqltkdsi) = jfrzdsvnqr ortbllgdpo (dyvjholoit )	-	08 May 2023
NCT02634307 (EVOLVE-MS-1, AAN2023)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	239	Diroximel Fumarate	dauufmnvft(sfljbxdzqw) = 23 (9.6%) patients discontinued DRF due to adverse events lhtjzjplwa (kmkdvkibjv ) View more	Positive	25 Apr 2023
NCT02634307 (EVOLVE-MS-1, AAN2023)	Phase 3	Multiple Sclerosis	1,057	Diroximel fumarate	fvzmpmpabb(srypchicux) = jgviyjqhan okhqeqrjbh (qqkpbcyeat ) View more	Positive	25 Apr 2023
				Placebo	fvzmpmpabb(srypchicux) = oqinupbsnv okhqeqrjbh (qqkpbcyeat ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis